Continuous Infusion of Remidazolam for Colonoscopic Polypectomy in Elderly Patients
Sedative Effect of Remidazolam Besylate Continuous Pump Infusion for Colonoscopic Polypectomy in Elderly Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: mujun Chang, Dr.
- Phone Number: 86-27-83663625
- Email: changmujun@hotmail.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430000
- Tongji Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 60-80 years old;
- ASA Level I - III;
- Operation time: 15min~1h;
- BMI18.0-29.9;
Exclusion Criteria:
- Emergency surgery;
- Patients with high risk of gastric satiety and reflux aspiration;
- Allergies to benzodiazepines and opioids;
- Those who have taken sedative, analgesic, or antidepressant drugs within 24 hours;
- Abnormal liver and kidney function;
- Previous drug use history;
- Recently participated in other clinical studies;
- Patients who cannot cooperate with communication.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Propofol group
propofol 2-3mg/kg/h
|
propofol 2-3mg/kg/h
Other Names:
|
|
Experimental: R1 group
remimazolam 0.5mg/kg/h
|
Using two different doses of remidazolam for continuous pumping to maintain anesthetic effect
Other Names:
|
|
Experimental: R2 group
remimazolam 0.75mg/kg/h
|
Using two different doses of remidazolam for continuous pumping to maintain anesthetic effect
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sedation success rate
Time Frame: 1 day
|
Evaluating the success rate of sedation using the modified MOAA/S scoring table
|
1 day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intraoperative time record
Time Frame: Intraoperative
|
Anesthesia time; Operation time; Wake up time; PACU time
|
Intraoperative
|
|
Drug usage
Time Frame: 1 day
|
doses of propofol,remimazolam and other drugs used
|
1 day
|
|
The incidence of adverse reactions during surgery
Time Frame: 1 day
|
includes: body movements, hypoxemia, hypotension, bradycardia; Intraoperative awareness
|
1 day
|
|
Incidence of postoperative adverse reactions
Time Frame: 24 hours after surgery
|
Postoperative nausea and vomiting, postoperative pain, hypotension, bradycardia, dizziness
|
24 hours after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: aihua Du, Dr., Tongji Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CIRC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.